http://www.law360.com/ Latest articles for organization: Teva Pharmaceutical Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/132544 The U.S. Department of Justice has named Leonard Grunstein, head of two real estate practice groups at Troutman Sanders LLP, as a defendant in a civil complaint in the still-unfolding case involving nursing home drug supply giant Omnicare Inc., which agreed Tuesday to pay $98 million to settle claims that it was part of a broad kickback scheme. http://www.law360.com/articles/132544 http://www.law360.com/articles/132454 Shire LLC has settled yet another patent infringement suit involving Carbatrol, this time by granting Apotex Inc. a license that will allow it to sell its own generic version of the epilepsy drug. http://www.law360.com/articles/132454 http://www.law360.com/articles/132144 Nursing home pharmacy giant Omnicare Inc. has agreed to shell out $98 million and a Teva Pharmaceutical Industries Ltd. unit has agreed to pay $14 million to settle claims that they were part of a wide-scale kickback conspiracy. http://www.law360.com/articles/132144 http://www.law360.com/articles/132090 Twin patent lawsuits brought by Hoffmann-La Roche Inc. accusing generic-drug maker Teva Pharmaceuticals USA Inc. and its Gate Pharmaceuticals division of infringing patents related to a popular osteoporosis drug have been dismissed because Teva dropped an application to make generic Boniva. http://www.law360.com/articles/132090 http://www.law360.com/articles/131102 Warner Chilcott PLC's allegations that Lupin Ltd. has infringed patents for its birth control drugs Loestrin 24 Fe and Femcon Fe will move forward in the U.S. District Court for the District of Delaware, now that the company has dropped identical protective suits in another court. http://www.law360.com/articles/131102 http://www.law360.com/articles/131475 British drugmaker Shire PLC has received a subpoena from U.S. investigators seeking documents related to the sales and marketing of three drugs, including Adderall, the company said. http://www.law360.com/articles/131475 http://www.law360.com/articles/131390 Abbott Laboratories has launched another suit seeking to block a generic version of its cholesterol drug TriCor, this one targeting generics maker Impax Laboratories Inc. http://www.law360.com/articles/131390 http://www.law360.com/articles/130896 A unit of specialty pharmaceutical firm Watson Pharmaceuticals Inc. has struck a deal with Barr Pharmaceuticals Inc. that resolves patent litigation over Watson’s Oxytrol and grants Barr a license to eventually market a generic version of the overactive bladder treatment. http://www.law360.com/articles/130896 http://www.law360.com/articles/130735 The U.S. Food and Drug Administration has warned drugmaker Sanofi-Aventis that a promotional advertisement for its prostate treatment Uroxatral misbrands the drug, in violation of the Federal Food, Drug and Cosmetic Act. http://www.law360.com/articles/130735 http://www.law360.com/articles/129705 Efforts by drugmaker Teva Pharmaceuticals USA Inc. to dismiss rival Novartis Pharmaceuticals Corp.'s patent infringement suit over generic herpes medications have been stymied in federal court following a judge's ruling that he did not have sufficient information to decide whether the plaintiffs had proper standing to bring the case. http://www.law360.com/articles/129705 http://www.law360.com/articles/129317 Alcon Inc. emerged victorious Tuesday from a three-year tussle with generic-drug maker Teva Pharmaceuticals USA Inc. over a patent related to the anti-bacterial drug Vigamox. http://www.law360.com/articles/129317 http://www.law360.com/articles/128868 The U.S. Court of Appeals for the Eighth Circuit is set to hear oral arguments Tuesday in a case that will decide whether failure-to-warn product liability claims against generic-drug manufacturers are preempted by federal law. http://www.law360.com/articles/128868 http://www.law360.com/articles/129102 Teva Pharmaceutical Industries Ltd. has hit Mylan Pharmaceuticals Inc. and Natco Pharma Ltd. with a patent infringement suit over their plans for a generic version of the multiple sclerosis therapy drug Copaxone. http://www.law360.com/articles/129102 http://www.law360.com/articles/128064 Irish drugmaker Shire PLC said Tuesday it had settled patent litigation over Sandoz Inc.'s abbreviated new drug application to market a generic version of Shire's attention deficit hyperactivity disorder drug Adderall XR. http://www.law360.com/articles/128064 http://www.law360.com/articles/127717 Teva Pharmaceutical Industries Ltd. has struck back with patent invalidity counterclaims against rival Gilead Sciences Inc. in an infringement case involving drug treatments for HIV. http://www.law360.com/articles/127717 http://www.law360.com/articles/127445 The Medicines Co. has sued Teva Pharmaceutical Industries Inc. over its plan to make a generic version of the Medicine Co.'s blood-thinning drug Angiomax. http://www.law360.com/articles/127445 http://www.law360.com/articles/126401 A judge has ruled that Sanofi-Aventis is bound to a settlement agreement it reached with Sun Pharmaceutical Industries Ltd. in a patent infringement suit over generic versions of Sanofi’s popular colon cancer drug Eloxatin, even though it failed to sign the agreement. http://www.law360.com/articles/126401 http://www.law360.com/articles/126727 European Commission officials raided several major drug manufacturers on Tuesday, reportedly including Sanofi-Aventis SA, as part of an investigation into anti-competitive practices. http://www.law360.com/articles/126727 http://www.law360.com/articles/125139 Following a recent rash of mergers, the top European Union competition official on Tuesday said pharmaceutical companies should “look out” for investigations in the coming months. http://www.law360.com/articles/125139 http://www.law360.com/articles/124772 Plaintiffs are seeking to obtain class status in a multidistrict litigation accusing Pfizer Inc. and its Warner-Lambert Co. subsidiary of using patent litigation to postpone generic competition for epilepsy treatment Neurontin. http://www.law360.com/articles/124772